Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. Issue 4 (16th August 2013)

• Record Type: Journal Article
• Authors: Boone, Brian A.; Steve, Jennifer; Krasinskas, Alyssa M.; Zureikat, Amer H.; Lembersky, Barry C.; Gibson, Michael K.; Stoller, Ronald G.; Zeh, Herbert J.; Bahary, Nathan
• Is Part Of: Journal of surgical oncology. Volume 108:Issue 4(2013:Sep. 15)
• Page Start: 236
• Page End: 241
• Publication Date: 2013-08-16
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23392
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jso23392-sec-0001" sec-type="section"> <title>Background</title> <p>Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine‐based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer.</p> </sec> <sec id="jso23392-sec-0002" sec-type="section"> <title>Methods</title> <p>Retrospective review of outcomes of patients with borderline resectable or locally unresectable pancreatic cancer who were recommended to undergo neoadjuvant treatment with FOLFIRINOX.</p> </sec> <sec id="jso23392-sec-0003" sec-type="section"> <title>Results</title> <p>FOLFIRINOX was recommended for 25 patients with pancreatic cancer, 13 (52%) unresectable and 12 (48%) borderline resectable. Four patients (16%) refused treatment or were lost to follow‐up. Twenty‐one patients (84%) were treated with a median of 4.7 cycles. Six patients (29%) required dose reductions secondary to toxicity. Two patients (9%) were unable to tolerate treatment and three patients (14%) had disease progression on treatment. Seven patients (33%) underwent surgical resection following treatment with FOLFIRINOX alone, 2 (10%) of which were initially unresectable. Two patients underwent resection following FOLFIRINOX + stereotactic body radiation therapy (SBRT). The R0 resection rate for patients treated with FOLFIRINOX ± SBRT was 33% (55% borderline resectable, 10% unresectable). A total of five patients (24%) demonstrated a significant pathologic response.</p> </sec> <sec id="jso23392-sec-0004" sec-type="section"> <title>Conclusions</title> <p>FOLFIRINOX is a biologically active regimen in borderline resectable and locally unresectable pancreatic cancer with encouraging R0 resection and pathologic response rates. <italic>J. Surg. Oncol. 2013 108:236–241</italic>. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>